Literature DB >> 3480077

Proliferation kinetics of plasma cells and of normal haemopoietic cells in multiple myeloma.

G Ucci1, A Riccardi, P Dörmer, M Danova, R Luoni, C M Montecucco, R Ciotti, M Girino.   

Abstract

DNA synthesis time (Ts) and 3H thymidine (TdR) labelling index (LI) of bone marrow (BM) myelomatous plasma cells (PC) and of the residual haemopoietic cell population (RHCP) were measured by in vitro quantitative 14C-TdR autoradiography in five patients with multiple myeloma (MM) in different phases of disease (three at presentation and two at relapse) and in one patient with solitary extra-osseous myeloma. One other patient with plasma cell leukaemia (PCL) was studied during an initial relapse phase and later during the leukaemic terminal phase. PC Ts was 18.8 +/- 3.7 (from 13.3 to 25.0) hr and PC LI was 2.5 +/- 1.8% (from 1.0 to 6.3%). In the case of PCL, circulating PC had a Ts of 14.4 hr and a LI of 3.1. From these experimental measurements, the fractional turnover rate (FTR-percentage of cells produced per unit time) and the potential doubling time (Td) of BMPC were calculated assuming that all BMPC were in a steady-state at the time of the study. BMPC FTR was 3.53 +/- 2.3% cells per day (from 1.2 to 6.72) and BMPC Td was 46.8 +/- 27.5 days (from 15.0 to 75.4). Comparison with results obtained in BM blasts of children with acute lymphoblastic leukaemia (ALL) indicated that BMPC had a lower proliferative activity (P less than 0.001), although BMPC Ts was not significantly different. In two patients a tumour doubling time of 6 and 13 months was determined by clinical follow up. Comparison of this parameter with Td showed a cell loss factor of more than 90% in both patients. Kinetic data relative to RHCP showed slight variations with respect to those found in normal subjects, with a general tendency towards a prolongation of Ts and a reduction of LI.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3480077     DOI: 10.1111/j.1365-2184.1987.tb01313.x

Source DB:  PubMed          Journal:  Cell Tissue Kinet        ISSN: 0008-8730


  1 in total

1.  Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.

Authors:  Nicolas Boissel; Patrice Chevallier; Vadim Doronin; Laimonas Griskevicius; Alexey Maschan; James McCloskey; Alessandro Rambaldi; Giuseppe Rossi; Andrey Sokolov; Ulla Wartiovaara-Kautto; Corina Oprea; Giovanni Abbadessa; Alice Gosselin; Sandrine Macé; Xavier Thomas
Journal:  Cancer Med       Date:  2022-02-02       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.